Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Repifermin. Human Genome Sciences/GlaxoSmithKline.

G Wheeler1

  • 1editor@greyowltutor.com

Idrugs : the Investigational Drugs Journal
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients' priorities in kidney stone disease.

Annals of the Royal College of Surgeons of England·2025
Same author

Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author

Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients.

Clinical oncology (Royal College of Radiologists (Great Britain))·2017
Same author

Detecting new microRNAs in human osteoarthritic chondrocytes identifies miR-3085 as a human, chondrocyte-selective, microRNA.

Osteoarthritis and cartilage·2015
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Repifermin, a keratinocyte growth factor-2 (KGF-2), is being developed for wound care, mucositis, and inflammatory bowel diseases. Clinical trials are underway for chronic venous ulcers, ulcerative colitis, and chemotherapy-induced mucositis.

Area of Science:

  • Biotechnology
  • Pharmacology
  • Regenerative Medicine

Background:

  • Repifermin, also known as keratinocyte growth factor-2 (KGF-2) or fibroblast growth factor-10 (FGF-10), is under development by Human Genome Sciences (HGS) and GlaxoSmithKline.
  • It is being investigated for potential therapeutic applications in wound care, oral and intestinal mucositis, and inflammatory bowel diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of repifermin in various clinical indications.
  • To assess the potential market and commercial viability of repifermin for treating chronic venous ulcers, mucositis, and ulcerative colitis.

Main Methods:

  • Phase IIb and Phase II clinical trials are ongoing for topical and systemic formulations of repifermin.
  • Clinical trials focus on chronic venous ulcers, ulcerative colitis, and mucositis prevention post-chemotherapy with bone marrow transplantation.

Related Experiment Videos

Main Results:

  • Market analysis predicts significant commercial potential for repifermin, with projected sales in the billions of dollars for various indications.
  • Specific sales forecasts are provided for venous ulcers, mucositis, and ulcerative colitis, with estimates for diabetic foot and pressure ulcers.

Conclusions:

  • Repifermin represents a substantial market opportunity for HGS/GlaxoSmithKline, with potential for significant revenue generation.
  • Further clinical development and regulatory approvals are anticipated for repifermin across its target indications.